



CLAIMS

1. Cetylpyridinium salt of diclofenac, of formula (I)



2. Cetylpyridinium salt of diclofenac⁻ (I) according to Claim 1, characterized in that it melts at 52-55°C.
3. Method comprising the preparation of the cetylpyridinium salt of diclofenac (I) according to the following scheme:



10

$$(I) + XY$$

in which

X is H or a mineral or organic cation, and

15 Y is OH or halogen,

in a suitable solvent, and separation of the salt (I) thus obtained via conventional techniques.

4. Method according to Claim 3, characterized in that X is an alkali metal.
- 20 5. Method according to Claim 3, characterized in that Y is Cl.
6. Method according to Claim 3, characterized in that the solvent is water.

- 10 -

7. Method according to Claim 3, characterized in that the solvent is a low molecular weight halohydrocarbon.
8. Method according to Claim 7, characterized in that the halohydrocarbon contains from 1 to 3 carbon atoms.
- 5 9. Method according to Claim 8, characterized in that the halohydrocarbon is selected from the group comprising methylene chloride, chloroform, carbon tetrachloride, dichloroethane, trichloroethane, tetrachloroethane, trichloroethylene and trichloropropane.
- 10 10. Pharmaceutical composition, characterized in that it contains an effective dose of cetylpyridinium salt of diclofenac (I) and at least one pharmaceutically acceptable inert ingredient.
11. Pharmaceutical composition according to Claim 9, characterized in that the cetylpyridinium salt of diclofenac (I) melts at 52-55°C.